C07C 311/11
Of an acyclic unsaturated carbon skeleton
Official title: of an acyclic unsaturated carbon skeleton
C07C311/11 (Of an acyclic unsaturated carbon skeleton) appears on 56 US grants and 49 published applications in this corpus.
Search patents in C07C- Granted patents
- 56
- Published applications
- 49
- Assignees
- 37
- Inventors
- 195
- Latest grant
- 9 Sep 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1994 | 2 | 0 |
| 1995 | 0 | 0 |
| 1996 | 1 | 0 |
| 1997 | 1 | 0 |
| 1998 | 4 | 0 |
| 1999 | 1 | 0 |
| 2000 | 2 | 0 |
| 2001 | 2 | 0 |
| 2002 | 8 | 3 |
| 2003 | 3 | 2 |
| 2004 | 3 | 5 |
| 2005 | 2 | 1 |
| 2006 | 4 | 1 |
| 2007 | 0 | 1 |
| 2008 | 2 | 1 |
| 2009 | 1 | 3 |
| 2010 | 2 | 1 |
| 2011 | 2 | 0 |
| 2012 | 0 | 0 |
| 2013 | 1 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 2 |
| 2017 | 2 | 2 |
| 2018 | 2 | 0 |
| 2019 | 1 | 2 |
| 2020 | 1 | 1 |
| 2021 | 1 | 4 |
| 2022 | 2 | 1 |
| 2023 | 3 | 9 |
| 2024 | 2 | 3 |
| 2025 | 1 | 2 |
| 2026 | 0 | 5 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Processes and intermediates for preparing MCL1 inhibitors9 Sep 2025US 12,410,146 B2Gilead Sciences, Inc.
- Cannabigerol derivatives and use thereof as cannabinoid receptor modulators10 Sep 2024US 12,084,407 B2Canopy Growth Corporation
- Compounds that inhibit MCL-1 protein2 Jul 2024US 12,024,529 B2Amgen Inc.
- Processes and intermediates for preparing MCL1 inhibitors19 Sep 2023US 11,760,736 B2Gilead Sciences, Inc.
- Compounds that inhibit MCL-1 protein27 Jun 2023US 11,685,747 B2Amgen Inc.
- Compounds and method for upregulation of p53 through induction of mdm2 degradation3 Sep 2026US 2026/0257987 A1Georgia State University Research Foundation, Inc.
- Probes and methods to identify ligandable fatty acylation sites for therapeutic target identification16 Apr 2026US 2026/0103438 A1
- Covalent, chemogenetic activators for k2p potassium channels and uses thereof9 Apr 2026US 2026/0098008 A1The Regents of the University of California
- Processes and intermediates for preparing mcl1 inhibitors26 Feb 2026US 2026/0055068 A1Gilead Sciences, Inc.
- Chemical compounds and uses thereof15 Jan 2026US 2026/0015321 A1Glaxosmithkline Intellectual Property (No. 4) Ltd.
Most cited
By later US patents
- α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors56US 6,248,775 B1G. D. Searle & Co. · 2001
- Sulfonamide and carboxamide derivatives and drugs containing the same as the active ingredient54US 6,448,290 B1Ono Pharmaceutical Co., Ltd. · 2002
- Irreversible covalent inhibitors of the GTPase K-Ras G12C44US 9,745,319 B2Araxes Pharma LLC · 2017
- .alpha.-and .beta.-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors43US 5,843,946 AG. D. Searle & Co. · 1998
- .alpha.- and .beta.-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors42US 6,060,476 AG. D. Searle & Co. · 2000